Table 2.

Multivariate Cox proportional hazard regression analysis for progression-free survival (PFS) and overall survival (OS) according to pre-treatment peripheral lymphocyte count.

	PFS		OS
	aHR (95% CI)	P	aHR (95% CI)	P
Age, years
< 65	1 (reference)		1 (reference)
65–74	0.57 (0.35, 0.94)	0.03	0.71 (0.42, 1.19)	0.19
≥ 75	0.56 (0.32, 0.97)	0.04	0.7 (0.38, 1.28)	0.25
Sex
Male	1 (reference)		1 (reference)	0.58
Female	1.14 (0.68, 1.91)	0.41	1.1 (0.63, 1.89)
Smoking status				0.75
Never	1 (reference)		1 (reference)
Ever	0.59 (0.35, 1.02)	0.04	0.85 (0.47, 1.52)
ECOG (ref 0)
0	1 (reference)		1 (reference)
1	1.54 (0.85, 2.81)	0.18	1.93 (0.96, 3.91)	0.12
≥ 2	2.37 (1.25, 4.51)	0.01	3.61 (1.78, 7.32)	0.001
Histology
Adenocarinoma	1 (reference)		1 (reference)
Squamous cell carcinoma	1.14 (0.59, 2.20)	0.63	1.00 (0.49, 2.03)	0.86
Other NSCLC	1.41 (0.83, 2.38)	0.32	2.02 (1.19, 3.42)	0.01
EGFR activating mutation	3.24 (1.80, 5.82)	< 0.001	1.90 (0.99, 3.66)	0.10
PD-L1 expression (≥ 1%)	0.43 (0.27, 0.69)	0.001	0.47 (0.28, 0.77)	0.002
Pre-treatment PLC Quartile [25th-75th]
1 [144.2–1041.9]	1 (reference)		1 (reference)
2 [1059.1–1524.4]	0.68 (0.40, 1.17)	0.26	0.53 (0.3, 0.93)	0.004
3 [1527.5–2070]	0.37 (0.20, 0.70)	0.004	0.25 (0.12, 0.51)	< 0.001
4 [2081.3–6241]	0.40 (0.23, 0.71)	0.002	0.36 (0.2, 0.66)	0.002
P for trend	0.006		0.035

PFS, progression-free survival; OS, overall survival; aHR, adjusted hazard ratio; CI, confidence interval; PLC, peripheral lymphocyte count.